A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation
Open Access
- 1 July 2007
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 7 (7), 1770-1777
- https://doi.org/10.1111/j.1600-6143.2007.01845.x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Chronic InductionPublished by S. Karger AG ,2004
- Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice1Transplantation, 2002
- Strategies to Improve Long-Term Outcomes after Renal TransplantationNew England Journal of Medicine, 2002
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- Anti-LFA-1α reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted ratsThe Journal of Heart and Lung Transplantation, 1999
- A RANDOMIZED MULTICENTER TRIAL COMPARING LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 MONOCLONAL ANTIBODY WITH RABBIT ANTITHYMOCYTE GLOBULIN AS INDUCTION TREATMENT IN FIRST KIDNEY TRANSPLANTATIONSTransplantation, 1996
- ADMINISTRATION OF AN ANTI-CD11a MONOCLONAL ANTIBODY IN RECIPIENTS OF KIDNEY TRANSPLANTATIONTransplantation, 1994
- Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1Science, 1992
- EFFECT OF ANTI-LFA1 (CD11a) MONOCLONAL ANTIBODIES IN ACUTE REJECTION IN HUMAN KIDNEY TRANSPLANTATIONTransplantation, 1991